Wanbury Ltd

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 28 Apr 2026. This adjustment reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to demonstrate robust financial performance and attractive valuation metrics, evolving technical indicators and certain risk factors have prompted a more cautious stance.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. This transition is underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages, suggesting a cautious yet optimistic outlook for investors as the stock navigates near-term resistance levels.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy by MarketsMOJO as of 23 April 2026. This upgrade is driven by a marked improvement in technical indicators, solid financial performance, attractive valuation metrics, and an overall enhanced quality assessment. Despite a recent day decline of 3.03%, the stock’s long-term fundamentals and technical outlook have strengthened, prompting a positive revision in its Mojo Score to 71.0.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish stance. Despite a 3.03% decline in the latest session, key technical indicators such as MACD, moving averages, and Bollinger Bands suggest an improving price momentum, signalling potential upside for investors amid mixed monthly signals.

At Rs 256.19, sellers were still queuing — but there were no buyers willing to take the other side. Wanbury Ltd locked at its lower circuit of 5% on 23 Apr 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock with limited liquidity.

At Rs 271.22, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Wanbury Ltd locked at its upper circuit of 5% on 22 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, moving averages, and Bollinger Bands, suggesting a nuanced outlook for investors as the stock navigates current market dynamics.

The 50-day moving average has crossed above the 200-day moving average for Wanbury Ltd, signalling a golden cross on 17 Apr 2026. Yet, the stock declined 2.61% on the day this technical event occurred, while monthly momentum indicators remain mildly bearish. This juxtaposition of signals calls for a detailed examination of whether the golden cross is a reliable indicator or a misleading signal in this context.

At Rs 252.45, sellers were still queuing — but there were no buyers willing to take the other side. Wanbury Ltd locked at its lower circuit of 5% on 17 Apr 2026, with unfilled sell orders and a frozen price that halted further decline.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively suggest a nuanced outlook for investors navigating the stock’s price action.

At Rs 277.65, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Wanbury Ltd locked at its upper circuit of 5.0% on 16 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 264.43, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Wanbury Ltd locked at its upper circuit of 5.0% on 15 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, suggesting cautious optimism among investors as the stock price advances to ₹252.45, up 4.99% on 15 Apr 2026.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 13 April 2026. This change reflects a notable improvement in the company’s technical indicators, financial trends, valuation metrics, and overall quality assessment, signalling a cautious but positive outlook for investors.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a bearish to a mildly bearish trend. Despite a 5.00% gain on 13 Apr 2026, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, prompting a recent downgrade in its Mojo Grade from Hold to Sell.